Biosite Inc.
San Diego, CA 92121
Share:
Testing Platform provides portable immunoassay solution.
Rapid testing platform, TriageÃ-® MeterPro(TM), provides quantitative or qualitative results for immunoassays using urine, whole-blood, or plasma. Along with built-in quality control capabilities, product features alphanumeric keypad, display, backlighting, and printing capabilities. Test Select(TM) feature lets healthcare providers customize test menus based on physician preference or...
Read More »Triage-® D-Dimer Test aids in assessment of PE and DVT.
TriageÃ-® D-Dimer Test aids emergency physicians in assessment and evaluation of patients suspected of having thromboembolic events, including pulmonary embolism (PE) and deep vein thrombosis (DVT). Portable, point-of-care diagnostic test provides D-dimer results in ~15 min and can be used in emergency department or at patient's bedside. It uses immunoassay technology and 3B6 D-dimer...
Read More »Biosite Determines That Revised Binding Offer from Inverness Constitutes a 'Superior Proposal'
SAN DIEGO, May 14: Biosite Incorporated (NASDAQ:BSTE) today announced that its Board of Directors has received a revised binding offer from Inverness Medical Innovations, Inc. (AMEX:IMA) to acquire, by way of a cash tender offer, 100% of the outstanding shares of common stock of Biosite not already owned by Inverness. The price contemplated by the Inverness offer is $92.50 per share in cash, plus...
Read More »Biosite Receives Revised Offer from Inverness Medical Regarding Possible Cash Tender Offer
SAN DIEGO, May 10 -- Biosite Incorporated (NASDAQ:BSTE) today announced that it has received a letter from Inverness Medical Innovations, Inc. (AMEX:IMA) contemplating an offer by Inverness to purchase, by way of a cash tender offer, 100% of the outstanding shares of common stock of Biosite not already owned by Inverness for $92.50 per share in cash. The letter was accompanied by a merger...
Read More »Biosite and Beckman Coulter Amend Definitive Merger Agreement
Beckman Coulter to Acquire Biosite in $90 Per Share Cash Tender Offer SAN DIEGO, May 2 -- Biosite Incorporated (NASDAQ:BSTE) today announced that it and Beckman Coulter, Inc. (NYSE:BEC) have entered into an amendment to their existing merger agreement dated March 24, 2007. Under the terms of the amendment to the merger agreement, Beckman Coulter will acquire all of Biosite's outstanding common...
Read More »Biosite Determines that Offer from Inverness Constitutes a 'Superior Proposal'
Beckman Coulter Has Right to Match Offer Under Merger Agreement SAN DIEGO, April 25 / -- Biosite Incorporated (NASDAQ:BSTE) today announced that it has received a binding offer from Inverness Medical Innovations, Inc. (AMEX:IMA) to enter into a merger transaction pursuant to which Inverness would acquire 100% of the outstanding shares of common stock of Biosite, other than Biosite shares already...
Read More »Biosite Announces Regulatory Clearance in Germany of Beckman Coulter Tender Offer
SAN DIEGO, April 24 / -- Biosite Incorporated (NASDAQ:BSTE) today announced that Beckman Coulter, Inc. (NYSE:BEC) has obtained clearance from the German Federal Cartel Office (the Bundeskartellamt) in connection with its proposed acquisition of Biosite pursuant to the tender offer described below. The tender offer is conditioned upon at least a majority of the outstanding Biosite shares,...
Read More »Biosite Announces Expiration of Hart-Scott-Rodino Waiting Period for Tender Offer With Beckman Coulter
SAN DIEGO, April 17: Biosite Incorporated (NASDAQ:BSTE) today announced that the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired without a request for additional information from the U.S. Federal Trade Commission with respect to the proposed acquisition of shares of Biosite by Beckman Coulter, Inc. (NYSE:BEC) pursuant to the tender offer described...
Read More »Biosite Incorporated Receives Further Revised Commitment Letters From Inverness Medical Regarding Possible Merger Transaction
SAN DIEGO, April 20: Biosite Incorporated (NASDAQ:BSTE) today announced that, on April 19, 2007, Inverness Medical Innovations, Inc. (AMEX:IMA) provided Biosite with copies of further revised commitment letters from Inverness' proposed financing sources in connection with the previously announced acquisition proposal made by Inverness to acquire all of Biosite's outstanding shares of common...
Read More »
Testing Platform provides portable immunoassay solution.
Rapid testing platform, TriageÃ-® MeterPro(TM), provides quantitative or qualitative results for immunoassays using urine, whole-blood, or plasma. Along with built-in quality control capabilities, product features alphanumeric keypad, display, backlighting, and printing capabilities. Test Select(TM) feature lets healthcare providers customize test menus based on physician preference or...
Read More »Triage-® D-Dimer Test aids in assessment of PE and DVT.
TriageÃ-® D-Dimer Test aids emergency physicians in assessment and evaluation of patients suspected of having thromboembolic events, including pulmonary embolism (PE) and deep vein thrombosis (DVT). Portable, point-of-care diagnostic test provides D-dimer results in ~15 min and can be used in emergency department or at patient's bedside. It uses immunoassay technology and 3B6 D-dimer...
Read More »